Arch Biopartners Inc

Arch Biopartners Inc is a clinical-stage company. Its pipeline consists of: MetaBlok that is a new drug candidate and potential treatment for inflammation, sepsis and cancer metastasis. AB569 is a new drug candidate for treating antibiotic-resistant bacterial infections, primarily in the lungs. BORG is a group of novel synthetic peptides and peptide conjugates that employ novel chemistry to react with solid surfaces such as metals, and plastics to generate new materials that display new surface properties. MetaMx is composed of a novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes and survival rates among glioblastoma patients.